Dr. Kim is the Director of the Interstitial Lung Disease program and supervises ILD clinical trials. She established the University of Minnesota ILD database in 2010 to answer questions about natural history and outcomes of ILD. She led the ILD program to achieve recognition as a Pulmonary Fibrosis Foundation Care Center Network site, which identifies pulmonary fibrosis centers that provide leading clinical care and research. She also organizes the University of Minnesota Pulmonary Fibrosis Patient Education Day, a biennial free symposium for patients and families with pulmonary fibrosis that provides the latest updates in pulmonary fibrosis care and research. Her clinical expertise centers on treating patients with interstitial lung disease, including idiopathic pulmonary fibrosis, chronic hypersensitivity pneumonitis, IgG4-related lung disease, airway-centered interstitial fibrosis, scleroderma lung disease, other connective tissue disease-related lung diseases and rare ILDs. Her research interests include natural history and outcomes in idiopathic pulmonary fibrosis, pharmacogenomics of anti-fibrotic medications, non-pharmacologic treatments for ILDs, and clinical trials in ILD.
Natural history of idiopathic pulmonary fibrosis; clinical predictors of disease progression and survival in idiopathic pulmonary fibrosis; clinical research in interstitial lung diseases. Predictors of survival in idiopathic pulmonary fibrosis; IgG4-related lung disease; risk factors for acute exacerbation of idiopathic pulmonary fibrosis; treatment ourcomes of pulmonary hypertension in interstitial lung diseases; airway-centered interstitial fibrosis; biomarkers of disease progression in idiopathic pulmonary fibrosis; multiple ongoing and completed clinical trials in idiopathic pulmonary fibrosis.
All ILDs. Our ILD clinic provides comprehensive, patient-centered care for patients. Our ILD nurse and clinic coordinators work closely with the ILD physicians to ensure that patients get the best care available. We also provide opportunities for patients to participate in studies if they choose.